In addition, several studies have shown that hormone receptor (HR)-positive patients with HER2-positive breast cancer are less sensitive to neoadjuvant chemotherapy plus HER2-targeted therapy than HR-negative patients, resulting in lower pCR rates and poorer DFS and OS [12, 17–21]. Here, ERBB2 is linked to breast carcinoma.